Skip to content
MedCompare

Lorlatinib

Also known as Lorbrena (us)

Cancer & Oncology
Save $11,510/mo
5× cheaper

Lorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC). Lorlatinib is in a class of medications called kinase inhibitors.

United States
$14,568
per month
India
$3,058
per month
You save
$11,510
79% cheaper in India
5.9K US scripts/yr$67.9M potential annual savings$85.9M US spend/yr
Building 3D structure…
Drag to rotate · 3D structureC21H19FN6O2

SMILES: C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C

Compare the price
US price$14,568per month
India price$3,058per month
You save$11,51079% less

Based on 30 units per month. US $485.61 vs India $101.93 per unit.

Total over 1 periodSave $11,510$14,568 → $3,058
Is travelling to India worth it?

The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.

Medicine savings over 6 months
$69,061
Estimated travel cost
− $2,300
Net savings after travel
$66,761

Even after travel, you could come out ahead by about $66,761.

Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.

The bigger picture

Lorlatinib is filled about 5.9K times a year under Medicare Part D. At the prices above, that works out to roughly:

Est. annual US spend
$85.9M
If sourced from India
$18M
Potential annual savings
$67.9M
−79%

Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.